Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
Marton König, Hilde Marie Torgauten, The Trung Tran, Trygve Holmøy, John Torgils Vaage, Fridtjof Lund‐Johansen, Gro Owren Nygaard
Abstract
This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.
Topics & Concepts
ImmunogenicityMultiple sclerosisCoronavirus disease 2019 (COVID-19)MedicineImmune systemSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Vaccination2019-20 coronavirus outbreakVirologyImmunologyOutbreakInfectious disease (medical specialty)DiseaseInternal medicineSARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesBacillus and Francisella bacterial research